A 52-week phase 2 trial on AMG133 in people with overweight and obesity is ongoing (NCT05669599)
Other information: Not recommended: - In case of convulsive disease
However, and despite these limitations, SGLT-2 inhibitors or a GLP-1RA with proven CV disease benefit are recommended in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7,8,9,10]
STEP-9 enrolled 407 adults with obesity and moderate knee osteoarthritis across 11 countries, randomly assigning them to semaglutide or placebo alongside lifestyle changes
10.1021/np9800102 230 ShulmanL
Prebiotics are a kind of non-digestible food ingredient that can improve host health by selectively stimulating the growth and/or activity of intestinal beneficial bacteria [164]